Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Sees Large Drop in Short Interest

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) was the target of a large drop in short interest in the month of December. As of December 15th, there was short interest totalling 1,570,000 shares, a drop of 29.6% from the November 30th total of 2,230,000 shares. Currently, 9.0% of the company’s shares are sold short. Based on an average daily trading volume, of 8,330,000 shares, the short-interest ratio is presently 0.2 days.

Insider Buying and Selling

In other Syros Pharmaceuticals news, Director Nancy A. Simonian sold 134,713 shares of Syros Pharmaceuticals stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $0.27, for a total transaction of $36,372.51. Following the transaction, the director now directly owns 41,070 shares of the company’s stock, valued at approximately $11,088.90. The trade was a 76.64 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 12.26% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in SYRS. GSA Capital Partners LLP acquired a new stake in Syros Pharmaceuticals in the third quarter valued at approximately $34,000. Acadian Asset Management LLC lifted its holdings in shares of Syros Pharmaceuticals by 101.5% in the 2nd quarter. Acadian Asset Management LLC now owns 34,578 shares of the company’s stock worth $178,000 after purchasing an additional 17,416 shares in the last quarter. Certuity LLC acquired a new stake in Syros Pharmaceuticals in the 2nd quarter valued at $109,000. Finally, Exome Asset Management LLC increased its stake in Syros Pharmaceuticals by 87.6% during the 3rd quarter. Exome Asset Management LLC now owns 298,575 shares of the company’s stock valued at $642,000 after purchasing an additional 139,400 shares in the last quarter. 91.47% of the stock is owned by institutional investors and hedge funds.

Syros Pharmaceuticals Trading Down 3.2 %

Shares of NASDAQ:SYRS traded down $0.01 during mid-day trading on Friday, hitting $0.21. The company had a trading volume of 5,146,148 shares, compared to its average volume of 2,356,837. The company has a debt-to-equity ratio of 1.97, a current ratio of 2.25 and a quick ratio of 2.25. Syros Pharmaceuticals has a one year low of $0.18 and a one year high of $8.17. The firm has a fifty day moving average price of $0.99 and a 200 day moving average price of $2.72. The company has a market capitalization of $5.61 million, a PE ratio of -0.07 and a beta of 1.33.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings results on Thursday, October 31st. The company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($0.76) by $0.08. During the same quarter in the prior year, the company earned ($1.35) earnings per share. As a group, research analysts forecast that Syros Pharmaceuticals will post -2.94 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. HC Wainwright reaffirmed a “neutral” rating and issued a $1.00 price objective (down from $6.00) on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. Brookline Capital Management restated a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. StockNews.com began coverage on shares of Syros Pharmaceuticals in a research note on Monday, December 23rd. They issued a “sell” rating on the stock. TD Cowen reissued a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. Finally, JMP Securities reaffirmed a “market perform” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $3.33.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.